December 5, 2025 – FACIT looks forward to working together with the Ontario Centre of Innovation (OCI) and the consortium of strategic commercialization organizations to expand support for health innovators and start-ups across the province. The MOU brings together 11 key strategic commercialization partners in Ontario’s life sciences ecosystem.
Tag: ecosystem
Idea to Investment Podcast: How FACIT’s support propels early cancer innovations
January 17, 2025 – FACIT’s David Koehler, Director of Fund Operations, appeared on TechAlliance’s Idea to Investment podcast along with Saumik Biswas, President, CEO and Founder of Tenomix Inc. based in London, Ontario. Tenomix’s advancements exemplifies how FACIT’s continuum of commercialization programs can strategically capitalize on homegrown talent and innovations to spur promising start-ups to grow roots in Ontario and bring cancer solutions to benefit patients sooner.
Read More from Idea to Investment Podcast: How FACIT’s support propels early cancer innovations
Esphera SynBio closes seed financing round to advance their lead designer cancer vaccine
January 7, 2025 – FACIT congratulates portfolio company, Esphera SynBio (“Esphera”), on successfully securing seed financing and strategic partners to continue developing bespoke cancer immunotherapies using their proprietary engineered exosome-based platform for improved vaccine efficacy.
FACIT investment in cTRL Therapeutics focuses cell therapy R&D on Ontario for patients with cancer
October 10, 2024 – cTRL Therapeutics announced it is strengthening its research and development operations in Canada. Following an investment by FACIT, the company will establish a state-of-the-art laboratory and leverage Ontario’s world-leading cancer research network to accelerate advancement of its cancer therapeutics pipeline to benefit patients sooner.